TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.13
−0.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.7M | 25.4M | 210.8M | 129.0M | — |
| Cost of Revenue | 40.1M | 4.1M | — | — | — |
| Gross Profit | (35.4M) | 21.3M | 210.8M | 129.0M | — |
| Operating Expenses | |||||
| R&D Expense | 140.7M | 142.3M | 125.3M | 99.9M | 66.6M |
| SG&A Expense | 40.5M | 41.0M | 38.5M | 32.3M | 30.6M |
| General & Admin Expense | 40.5M | 41.0M | 38.5M | 32.3M | 30.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (40.1M) | (6.0M) | — | — | — |
| Total Operating Expenses | 141.2M | 177.3M | 163.8M | 132.2M | 97.2M |
| Cost and Expenses | 181.2M | 181.4M | 163.8M | 132.2M | 97.2M |
| Operating Income (EBIT) | (176.5M) | (156.0M) | 47.0M | (3.2M) | (97.2M) |
| Non-Operating | |||||
| Interest Income | 11.6M | — | 19.5M | 15.2M | 2.6M |
| Interest Expense | — | — | — | — | 2.6M |
| Net Interest Income | 11.6M | — | 19.5M | 15.2M | — |
| Other Non-Op Income/Expense | 11.6M | 13.2M | 19.5M | 15.2M | 2.6M |
| Non-Operating Income (excl Interest) | (11.6M) | (13.2M) | (19.5M) | (15.2M) | (5.3M) |
| EBT (Pre-Tax Income) | (165.0M) | (142.8M) | 66.5M | 12.1M | (94.6M) |
| Income Tax Expense | 819.0K | 924.0K | 859.0K | 18.7M | — |
| Bottom Line | |||||
| Net Income | (165.8M) | (143.8M) | 65.6M | (6.7M) | (94.6M) |
| Earnings from Cont. Ops | (165.8M) | (143.8M) | 65.6M | (6.7M) | (94.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (165.8M) | (143.8M) | 65.6M | (6.7M) | (94.6M) |
| Per Share | |||||
| Basic EPS | ($3.97) | ($3.47) | $1.76 | ($0.20) | ($2.79) |
| Diluted EPS | ($3.97) | ($3.47) | $1.68 | ($0.20) | ($2.79) |
| Revenue Per Share | $0.11 | $0.61 | $5.65 | $3.90 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 42.2M | 41.4M | 37.3M | 33.1M | 31.3M |
| Diluted Shares Outstanding | 42.2M | 41.4M | 39.0M | 33.1M | 31.3M |
| Profitability Metrics | |||||
| EBITDA | (164.9M) | (142.4M) | 70.3M | 14.9M | (90.1M) |
| D&A | 91.0K | 425.0K | 3.8M | 2.8M | 1.9M |
| EBIT | (165.0M) | (142.8M) | 66.5M | 12.1M | (92.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026